Management and Survival Trends in Advanced Colorectal Cancer

Clinical Oncology

Volumn 20, Issue 8, 2008, Pages 626-630

  Price, T ^a,b   Pittman, K ^a   Patterson, W ^a,b   Colbeck, M ^a   Rieger, N ^a   Hewett, P ^a   Rodda, D ^a   Townsend, A ^a   Maddern, G ^a   Luke, C ^c   Roder, D ^d  

^a QUEEN ELIZABETH HOSPITAL   (Australia)

^b LYELL MCEWIN HOSPITAL   (Australia)

^c Department of Health ^*  (Australia)

^d Cancer Council SA   (Australia)

Author keywords

Chemotherapy; clinical trials; colorectal cancer; elderly; hepatic surgery; survival

Indexed keywords

CAPECITABINE; FLOXURIDINE; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MITOMYCIN C; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; COLORECTAL CANCER; COLORECTAL SURGERY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; HUMAN; LIVER METASTASIS; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; SURVIVAL TIME; TREND STUDY;

AGED; AGED, 80 AND OVER; CAMPTOTHECIN; COLORECTAL NEOPLASMS; HUMANS; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; SURVIVAL ANALYSIS;

EID: 51249086234     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2008.04.014     Document Type: Article

References (16)

1. Scheithauer W., Rosen H., Kornek G.V., et al. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. Br Med J 306 6880 (1993) 752-755
2. Meta-analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 16 1 (1998) 301-308
3. Goldberg R.M., Sargent D.J., Morton R.F., et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22 1 (2004) 23-30
4. Tournigand C., Andre T., Achille E., et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22 2 (2004) 229-237
5. Simmonds P.C., Primrose J.N., Colquitt J.L., et al. Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer 94 7 (2006) 982-999
6. Gondos A., Arndt V., Holleczek B., et al. Cancer survival in Germany and the United States at the beginning of the 21st century: an up-to-date comparison by period analysis. Int J Cancer 121 2 (2007) 395-400
7. Luke C.G., Koczwara B., Moore J.E., et al. Treatment and survival from colorectal cancer: the experience of patients at South Australian teaching hospitals between 1980 and 2002. Clin Oncol 17 (2005) 372-381
8. Rothenberg M.L., Eckardt J.R., Kuhn J.G., et al. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 14 4 (1996) 1128-1135
9. Cunningham D., Pyrhonen S., James R.D., et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352 9138 (1998) 1413-1418
10. Price T.J., Pittman K., Patterson K., et al. Survival and treatment trends for advanced colorectal cancer treatment in a university hospital, 1992-2001. J Clin Oncol 22 Suppl (2004) 3707a
11. Koeller J.M., Kwan P., McKibbin T., et al. Advanced colorectal cancer treatment and outcome in the community oncology setting. J Clin Oncol 20 24 (2006) 16040a
12. Grothey A., Sargent D., Goldberg R.M., et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22 7 (2004) 1209-1214
13. Saltz L.B., Cox J.V., Blanke C., et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343 13 (2000) 905-914
14. Hebert-Croteau N., Brisson J., Lemaire J., et al. The benefit of participating to clinical research. Br J Cancer Res Treat 91 3 (2005) 279-281
15. Peppercorn J., Weeks J., Cook E.F., et al. Comparison of outcomes in cancer patients within and outside clinical trials: conceptual framework and structured review. Lancet 363 (2004) 263-270
16. Michael M., Goldstein D., Clarke S.J., et al. Prognostic factors predictive of response and survival to a modified FOLFOX regimen: importance of an increased neutrophil count. Clin Colorectal Cancer 6 (2006) 297-304